How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6)

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about asfotase alfa

    Marketing authorisation indication

    2.1 Asfotase alfa (Strensiq, Alexion Pharma UK) is indicated for "long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease".

    Dosage in the marketing authorisation

    2.2 The dosage schedule is available in the summary of product characteristics for asfotase alfa.

    Price

    2.3 The list prices for asfotase alfa are:

    • £12,700.80 per 12-injection vial, which contains 18 mg/0.45 ml of asfotase alfa (excluding VAT; BNF online, accessed October 2022)

    • £19,756.80 per 12-injection vial, which contains 28 mg/0.7 ml of asfotase alfa (excluding VAT; BNF online, accessed October 2022)

    • £28,224.00 per 12-injection vial, which contains 40 mg/1 ml of asfotase alfa (excluding VAT; BNF online, accessed October 2022)

    • £56,448.00 per 12-injection vial, which contains 80 mg/0.8 ml of asfotase alfa (excluding VAT; BNF online, accessed October 2022).

      The company has a commercial arrangement (simple discount patient access scheme). This makes asfotase alfa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.